Cargando…
Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
PURPOSE OF REVIEW: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject...
Autores principales: | Rico-Mesa, Juan Simon, White, Averi, Anderson, Allen S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154066/ https://www.ncbi.nlm.nih.gov/pubmed/32291526 http://dx.doi.org/10.1007/s11886-020-01291-4 |
Ejemplares similares
-
The Role of Anticoagulation in COVID-19-Induced Hypercoagulability
por: Rico-Mesa, Juan Simon, et al.
Publicado: (2020) -
Oncology During the COVID-19 Pandemic: a Lockdown Perspective
por: Boniface, Danielle, et al.
Publicado: (2022) -
Patient-related outcomes in patients referred to a respiratory clinic
with persisting symptoms following non-hospitalised COVID-19
por: Harvey-Dunstan, Theresa C, et al.
Publicado: (2022) -
Medical Nutrition Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection in a Non-critical Care Setting: Knowledge in Progress
por: Cervantes-Pérez, Enrique, et al.
Publicado: (2020) -
Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
Publicado: (2021)